
Moderna's personalised mRNA melanoma vaccine succeeds in a phase 3 trial
Moderna and Merck presented the first phase 3 study showing a customised mRNA therapy, intismeran, could improve outcomes for patients with melanoma, at ESMO in Madrid. 'Most people in the field thought this was never going to work,' CEO Stephane Bancel told STAT, after 10 years of work.
Read more at STAT →















